Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,497.80
+54.10 (3.75%)
Jun 19, 2026, 3:30 PM IST
Aurobindo Pharma Market Cap
Aurobindo Pharma has a market cap or net worth of 861.8 billion as of June 18, 2026. Its market cap has increased by 29.27% in one year.
Market Cap
861.80B
Enterprise Value
836.27B
Revenue
336.53B
Ranking
n/a
PE Ratio
24.82
Stock Price
1,497.80
Market Cap Chart
Since July 1, 2002, Aurobindo Pharma's market cap has increased from 9.60B to 861.80B, an increase of 8,874.03%. That is a compound annual growth rate of 20.62%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 19, 2026 | 861.80B | 25.43% |
| Dec 31, 2025 | 687.09B | -11.35% |
| Dec 31, 2024 | 775.08B | 22.03% |
| Dec 29, 2023 | 635.16B | 147.32% |
| Dec 30, 2022 | 256.82B | -40.31% |
| Dec 31, 2021 | 430.28B | -20.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Divi's Laboratories | 1.77T |
| Cipla | 1.09T |
| Zydus Lifesciences | 1.08T |
| Mankind Pharma | 993.26B |
| Laurus Labs | 739.50B |
| Alkem Laboratories | 639.37B |
| Glenmark Pharmaceuticals | 607.86B |
| Ipca Laboratories | 390.37B |